Autolus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Autolus Therapeutics
AUTL Stock  USD 1.53  0.20  15.04%   
Autolus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Autolus Therapeutics' valuation are provided below:
Gross Profit
-150 M
Market Capitalization
393.9 M
Enterprise Value Revenue
34.9829
Revenue
9 M
Earnings Share
(0.88)
There are over one hundred nineteen available fundamental signals for Autolus Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to validate Autolus Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2025. Market Cap is expected to rise to about 749.9 M this year. Enterprise Value is expected to rise to about 543.9 M this year

Autolus Therapeutics Total Revenue

10.63 Million

Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 6.8 M or Selling General Administrative of 106.1 M, as well as many indicators such as Price To Sales Ratio of 56.29, Dividend Yield of 0.0 or PTB Ratio of 1.33. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Autolus Stock
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Autolus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets821.9 M782.7 M311.6 M
Slightly volatile
Other Current Liabilities57.9 M55.2 M21.5 M
Slightly volatile
Total Current Liabilities63.8 M60.7 M24.2 M
Slightly volatile
Total Stockholder Equity222 M427.3 M203.9 M
Slightly volatile
Net Tangible Assets213.2 M343.5 M226.3 M
Pretty Stable
Property Plant And Equipment Net110.3 M105.1 M39.3 M
Slightly volatile
Accounts Payable2 M2 M4.9 M
Slightly volatile
Cash207.8 M227.4 M190.2 M
Slightly volatile
Non Current Assets Total127.9 M121.8 M47.3 M
Slightly volatile
Cash And Short Term Investments617.4 M588 M238.3 M
Slightly volatile
Net Receivables50.7 M48.2 M13.2 M
Slightly volatile
Common Stock Shares Outstanding267.9 M255.2 M74.3 M
Slightly volatile
Liabilities And Stockholders Equity821.9 M782.7 M311.6 M
Slightly volatile
Other Current Assets16.4 M21.5 M11.5 M
Slightly volatile
Other Stockholder Equity3.3 B3.1 B720.5 M
Slightly volatile
Total Liabilities373.2 M355.4 M93.5 M
Slightly volatile
Total Current Assets694 M660.9 M264.3 M
Slightly volatile
Intangible Assets11.7 M11.1 M8.2 M
Very volatile
Common Stock12.6 K12 K3.7 K
Slightly volatile
Property Plant Equipment36.1 M67.2 M32 M
Slightly volatile
Short and Long Term Debt Total55.3 M52.6 M18 M
Slightly volatile
Other Liabilities152.2 M144.9 M43.5 M
Slightly volatile
Non Current Liabilities Total309.4 M294.7 M69.5 M
Slightly volatile
Capital Surpluse325.1 M575.6 M385.6 M
Slightly volatile
Property Plant And Equipment Gross146.7 M139.7 M51.5 M
Slightly volatile
Non Current Liabilities Other256.8 M244.6 M61.8 M
Slightly volatile
Net Invested Capital276.9 M427.3 M254.9 M
Pretty Stable
Preferred Stock Total Equity1.1 K1.1 K52.2 K
Slightly volatile
Net Working Capital315.7 M600.2 M268 M
Slightly volatile
Other Assets1.091.151.4 M
Slightly volatile
Common Stock Total Equity2.6 K2.7 K9.7 K
Very volatile
Capital Stock6.1 K12 K3.8 K
Slightly volatile
Capital Lease Obligations42.4 M52.6 M31.9 M
Slightly volatile
Short Term Debt4.6 M3 M5.3 M
Very volatile

Autolus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.9 M7.7 M3.6 M
Slightly volatile
Selling General Administrative106.1 M101.1 M32 M
Slightly volatile
Total Revenue10.6 M10.1 M2.7 M
Slightly volatile
Other Operating Expenses263.5 M250.9 M103.9 M
Slightly volatile
Research Development88.3 M138.4 M66.9 M
Slightly volatile
Total Operating Expenses251.5 M239.5 M90.3 M
Slightly volatile
Interest Income34 M32.4 M5.8 M
Slightly volatile
Reconciled Depreciation5.9 M7.7 M4 M
Slightly volatile
Selling And Marketing Expenses877.6 K987.3 K1.1 M
Slightly volatile

Autolus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation4.8 M7.7 M3.6 M
Slightly volatile
Capital Expenditures36.6 M34.8 M12.1 M
Slightly volatile
End Period Cash Flow208 M228.8 M190.3 M
Slightly volatile
Stock Based Compensation12.6 M15.5 M9.5 M
Slightly volatile
Begin Period Cash Flow193.6 M240.3 M154.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio56.2959.25181.4 K
Slightly volatile
PTB Ratio1.331.40327.675
Slightly volatile
Days Sales Outstanding1.7 K1.7 K4 K
Pretty Stable
Book Value Per Share1.591.67473.3681
Very volatile
Stock Based Compensation To Revenue1.451.52898.5932
Pretty Stable
Capex To Depreciation3.324.51262.4014
Slightly volatile
PB Ratio1.331.40327.675
Slightly volatile
Payables Turnover5.495.783144.9081
Slightly volatile
Sales General And Administrative To Revenue35.930.9239.4388
Pretty Stable
Research And Ddevelopement To Revenue13.013.679461.421
Pretty Stable
Capex To Revenue3.273.44069.0215
Very volatile
Cash Per Share4.252.30453.1682
Slightly volatile
Days Payables Outstanding59.9663.1145476
Slightly volatile
Income Quality0.620.93480.6861
Slightly volatile
Intangibles To Total Assets0.01730.01820.1684
Slightly volatile
Net Debt To EBITDA0.910.95792.1571
Slightly volatile
Current Ratio12.7210.880710.1203
Pretty Stable
Tangible Book Value Per Share1.541.62623.0672
Pretty Stable
Receivables Turnover0.20.20985.0492
Slightly volatile
Shareholders Equity Per Share1.591.67473.3681
Very volatile
Debt To Equity0.0960.12320.0841
Slightly volatile
Capex Per Share0.20.13650.1679
Slightly volatile
Revenue Per Share0.05170.03970.0385
Pretty Stable
Interest Debt Per Share0.280.24270.2574
Slightly volatile
Debt To Assets0.05230.06720.0472
Slightly volatile
Operating Cycle1.8 K1.9 K4.1 K
Pretty Stable
Price Book Value Ratio1.331.40327.675
Slightly volatile
Days Of Payables Outstanding59.9663.1145476
Slightly volatile
Ebt Per Ebit0.780.90770.9657
Pretty Stable
Company Equity Multiplier1.21.83171.3629
Slightly volatile
Long Term Debt To Capitalization9.0E-40.0010.0011
Slightly volatile
Total Debt To Capitalization0.07790.10970.0674
Slightly volatile
Debt Equity Ratio0.0960.12320.0841
Slightly volatile
Quick Ratio12.6810.812610.0773
Pretty Stable
Net Income Per E B T0.721.0070.8915
Pretty Stable
Cash Ratio3.563.74338.2467
Very volatile
Days Of Sales Outstanding1.7 K1.7 K4 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.291.16881.1905
Slightly volatile
Price To Book Ratio1.331.40327.675
Slightly volatile
Fixed Asset Turnover0.130.09630.1115
Pretty Stable
Debt Ratio0.05230.06720.0472
Slightly volatile
Price Sales Ratio56.2959.25181.4 K
Slightly volatile
Asset Turnover0.01120.01290.0087
Pretty Stable
Price Fair Value1.331.40327.675
Slightly volatile

Autolus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap749.9 M599.6 M831.1 M
Slightly volatile
Enterprise Value543.9 M424.9 M642.1 M
Slightly volatile

Autolus Fundamental Market Drivers

Cash And Short Term Investments588 M

Autolus Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Autolus Therapeutics Financial Statements

Autolus Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Autolus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.9 M-5.6 M
Total Revenue10.1 M10.6 M
Cost Of Revenue11.4 M10.8 M
Stock Based Compensation To Revenue 1.53  1.45 
Sales General And Administrative To Revenue 30.92  35.90 
Research And Ddevelopement To Revenue 13.68  13.00 
Capex To Revenue 3.44  3.27 
Revenue Per Share 0.04  0.05 
Ebit Per Revenue(23.86)(25.05)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:
How To Invest In Autolus
Details
Is Autolus Stock a good investment?
Details
What is Autolus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.88)
Revenue Per Share
0.034
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.20)
Return On Equity
(0.50)
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY